Format

Send to

Choose Destination
See comment in PubMed Commons below
J Clin Oncol. 1994 Jan;12(1):60-3.

Oral etoposide is active against platinum-resistant epithelial ovarian cancer.

Author information

1
Division of Medical Oncology and Gynecologic Oncology, British Columbia Cancer Agency, Vancouver, Canada.

Abstract

PURPOSE:

To determine whether etoposide (VP16) is more effective when administered on a chronic schedule, women with clinically defined platinum-resistant epithelial ovarian cancer (EOC) were studied.

PATIENTS AND METHODS:

Thirty-one eligible women were treated with oral VP16. The first seven received a dose that varied depending on their body-surface area, but this proved too toxic, and so a fixed dose of 100 mg orally per day for 14 days every 3 weeks was used for the other subjects.

RESULTS:

The response rate was 26% (95% confidence interval [CI], 11% to 41%). The 28 women with cancer that had progressed while they were receiving a platinum analog had a response rate of 21% (95% CI, 6% to 36%). Response durations were short.

CONCLUSION:

When administered on this chronic schedule, VP16 has activity against platinum-resistant EOC.

PMID:
8270985
DOI:
10.1200/JCO.1994.12.1.60
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center